Literature DB >> 12436471

Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.

Emanuele Nicastri1, Loredana Sarmati, Gabriella d'Ettorre, Lucia Palmisano, Saverio G Parisi, Ilaria Uccella, Alessia Rianda, Ercole Concia, Vincenzo Vullo, Stefano Vella, Massimo Andreoni.   

Abstract

The fitness of human immunodeficiency virus (HIV) in vivo depends on the interaction of a multitude of viral and host factors. The aim of this study was to analyze the biological phenotype and the intrinsic capacity of the HIV isolates with drug-resistance mutations to replicate efficiently in the absence of drugs. An open label multicenter cross-sectional study was undertaken on 28 HIV-infected patients failing antiretroviral treatment. The subjects were studied for CD4+ cell count, HIV viral load, syncytium-inducing phenotype, genotypic drug-resistance assay, and replication capacity of HIV isolates assessed by co-culture assay. All HIV isolates showed a decreased replication capacity compared with wild-type strains. The lowest replication capacity was detected in HIV strains with more than five drug-resistance mutations. The highest replication capacity was observed in strains carrying the K103N and Y181C primary mutations that emerged after treatment with non-nucleoside analogue inhibitors. Isolates with R5 biological phenotype had a higher number of resistant mutations than X4 isolates (P = 0.004). Particularly, the R5 phenotype was detected in all 6 isolates with more than 14 drug-resistance mutations. Patients with R5 strains had plasma viral load similar to patients with X4 strains, but marginally higher CD4+ cell counts, and their HIV isolates had significantly lower replication capacity of HIV isolates (P = 0.008). No patient carrying HIV with a maintained replication capacity had a viral load less than 30,000 copies/ml. In patients failing HAART, the detection of HIV isolates with the R5 biological phenotype correlates with CD4+ cell count, an impaired replication capacity, and a high number of drug-resistance mutations. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12436471     DOI: 10.1002/jmv.10269

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  18 in total

1.  Drug-associated resistance mutations in plasma and peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected patients for whom highly active antiretroviral therapy is failing.

Authors:  Loredana Sarmati; Emanuele Nicastri; Ilaria Uccella; Gabriella D'Ettorre; Saverio G Parisi; Lucia Palmisano; Clementina Galluzzo; Ercole Concia; Vincenzo Vullo; Stefano Vella; Massimo Andreoni
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

2.  Fluorescent dye terminator sequencing methods for quantitative determination of replication fitness of human immunodeficiency virus type 1 containing the codon 74 and 184 mutations in reverse transcriptase.

Authors:  Viktoria Nurpeisov; Selwyn J Hurwitz; Prem L Sharma
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

3.  Differential impact of resistance-associated mutations to protease inhibitors and nonnucleoside reverse transcriptase inhibitors on HIV-1 replication capacity.

Authors:  Szu-Min Hsieh; Sung-Ching Pan; Sui-Yuan Chang; Chien-Ching Hung; Wang-Huei Sheng; Mao-Yuan Chen; Shan-Chwen Chang
Journal:  AIDS Res Hum Retroviruses       Date:  2013-05-15       Impact factor: 2.205

4.  Detection of human immunodeficiency virus (HIV) type 1 M184V and K103N minority variants in patients with primary HIV infection.

Authors:  Thomas A Toni; Eugene L Asahchop; Daniela Moisi; Michel Ntemgwa; Maureen Oliveira; Bernard Masquelier; Bluma G Brenner; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

5.  High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis.

Authors:  Emanuele Nicastri; Loredana Sarmati; Gabriella d'Ettorre; Saverio G Parisi; Lucia Palmisano; Clementina Galluzzo; Marco Montano; Ilaria Uccella; Roberta Amici; Francesca Gatti; Vincenzo Vullo; Ercole Concia; Stefano Vella; Massimo Andreoni
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

6.  Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases.

Authors:  Luis M F Gonzalez; Rodrigo M Brindeiro; Renato S Aguiar; Helena S Pereira; Celina M Abreu; Marcelo A Soares; Amilcar Tanuri
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

7.  Drug-class specific impact of antivirals on the reproductive capacity of HIV.

Authors:  Max von Kleist; Stephan Menz; Wilhelm Huisinga
Journal:  PLoS Comput Biol       Date:  2010-03-26       Impact factor: 4.475

8.  Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants.

Authors:  Jessica Marinello; Christophe Marchand; Bryan T Mott; Anjali Bain; Craig J Thomas; Yves Pommier
Journal:  Biochemistry       Date:  2008-08-15       Impact factor: 3.162

9.  Relationship of injection drug use, antiretroviral therapy resistance, and genetic diversity in the HIV-1 pol gene.

Authors:  Jeanne Kowalski; Stephen J Gange; Michael F Schneider; Hua-Ling Tsai; Alan Templeton; Qiujia Shao; Guang Wen Zhang; Mei-Fen Yeh; Mary Young; Richard B Markham
Journal:  J Acquir Immune Defic Syndr       Date:  2009-04-01       Impact factor: 3.731

10.  Replication and drug resistant mutation of HIV-1 subtype B' (Thailand B) variants isolated from HAART treatment individuals in China.

Authors:  Jianping Sun; Liying Ma; Xiaoling Yu; Yang Huang; Lin Yuan; Yiming Shao
Journal:  Virol J       Date:  2009-11-18       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.